Roivant Sciences (ROIV) investor relations material

Strategic evolution and business model

• Transitioned from specialty pharma to immunology and pulmonology, focusing on multi-indication franchises like brepocitinib and IMVT-1402.

• Developed core competence in indication selection and aggressive clinical development, enabling robust multi-indication pipelines.

• Maintains an opportunistic, flexible approach, building on existing assets and adapting as the company scales.

• Aims for long-term growth through commercialization and profitability, moving beyond exits to a standalone biotech model.

• Current pipeline is considered highly aligned with successful biotech commercialization trends.

Capital allocation and financial strategy

• Well-capitalized post-TL1A divestiture, with a balanced approach: one-third to shareholders, one-third to new opportunities, one-third to existing pipeline.

• Accelerated share buybacks in anticipation of Moderna settlement proceeds, with $1.5 billion repurchased at $10/share.

• Additional capital would likely be returned to shareholders, as current resources are sufficient for ongoing plans.

R&D and business development priorities

• Focused on expanding indications for brepocitinib and IMVT-1402, leveraging strong biology and capital position.

• Maintains a "ruthlessly economic" R&D culture, prioritizing high-quality investments regardless of company scale or cash flow improvements.

• Seeks to avoid the pitfalls of large pharma by making capital decisions based on intrinsic value, not investor optics.